VERADIGM INC (MDRX)
(Delayed Data from OTC)
$9.50 USD
0.00 (0.00%)
Updated Aug 14, 2024 03:59 PM ET
3-Hold of 5 3
B Value C Growth D Momentum B VGM
Brokerage Reports
Veradigm Inc. [MDRX]
Reports for Purchase
Showing records 41 - 60 ( 600 total )
Company: Veradigm Inc.
Industry: Medical Info Systems
Optimized Entry and Exit Levels for MDRX 72123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Veradigm Inc.
Industry: Medical Info Systems
Provider: Zacks Investment Research
Analyst: Research Department
Company: Veradigm Inc.
Industry: Medical Info Systems
Company: Veradigm Inc.
Industry: Medical Info Systems
Optimized Entry and Exit Levels for MDRX 71123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Veradigm Inc.
Industry: Medical Info Systems
Company: Veradigm Inc.
Industry: Medical Info Systems
Company: Veradigm Inc.
Industry: Medical Info Systems
Proprietary Healthcare Credit Card Transaction Data
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Veradigm Inc.
Industry: Medical Info Systems
Company: Veradigm Inc.
Industry: Medical Info Systems
Company: Veradigm Inc.
Industry: Medical Info Systems
Extension Granted to File Its 10-K and 10-Q; Expected $40 Million Revenue Impact Not Increased Despite Further Review
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Veradigm Inc.
Industry: Medical Info Systems
Company: Veradigm Inc.
Industry: Medical Info Systems
Company: Veradigm Inc.
Industry: Medical Info Systems
Proprietary Healthcare Credit Card Transaction Data
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Veradigm Inc.
Industry: Medical Info Systems
Provider: Zacks Investment Research
Analyst: Research Department
Company: Veradigm Inc.
Industry: Medical Info Systems
Company: Veradigm Inc.
Industry: Medical Info Systems
Company: Veradigm Inc.
Industry: Medical Info Systems
Healthcare IT: Proprietary Healthcare Credit Card Transaction Data
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Veradigm Inc.
Industry: Medical Info Systems
Adjusting Estimates as Audit Review Continues with Impact on Share Repurchases vs. Prior Estimates
Provider: KeyBanc Capital Markets
Analyst: Research Department